Asymmetric catalysis in the pharmaceutical industry

Angewandte Chemie - International Edition

Volumn 43, Issue 25, 2004, Pages 3224-3228

  Hawkins, Joel M ^a   Watson, Timothy J N ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Asymmetric catalysis; Chiral auxiliaries; Freedom to operate; Hydrogenation; Industrial processes

Indexed keywords

CATALYSIS; HYDROGENATION; SYNTHESIS (CHEMICAL);

PHARMACEUTICAL INDUSTRY;

DRUG PRODUCTS PLANTS;

ANTIDIABETIC AGENT; CANDOXATRIL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; SERTRALINE;

ASYMMETRIC CATALYSIS; CATALYST; CHEMICAL MODIFICATION; CHROMATOGRAPHY; DRUG DESIGN; DRUG INDUSTRY; ENANTIOMER; HYDROGENATION; REVIEW; STEREOCHEMISTRY;

CATALYSIS; DRUG DESIGN; DRUG INDUSTRY; MOLECULAR STRUCTURE;

EID: 4544260095     PISSN: 14337851     EISSN: None     Source Type: Journal    
DOI: 10.1002/anie.200330072     Document Type: Review

References (27)

1. As early as 1997, the increased tendency to patent synthetic methodology was noted to be "creating a complex legal maze for the chemical industry." D. B. Collum in 1997 Yearbook of Science and the Future (Ed.: D. Calhoun), Encyclopedia Britannica, Chicago, 1996, p. 284.
2. M. K. O'Brien, B. Vanasse, Curr. Opin. Drug Discovery Dev. 2000, 3, 793.
3. For a detailed analysis illustrated with many examples including the use of enzymes, see reference [2].
4. A. Collet, Angew. Chem. 1998, 110, 3429; Angew. Chem. Int. Ed. 1998, 37, 3239.
5. A. Collet, Angew. Chem. 1998, 110, 3429; Angew. Chem. Int. Ed. 1998, 37, 3239.
6. T. Vries, H. Wynberg, E. van Echten, J. Koek, W. ten Hoeve, R. M. Kellogg, Q. M. Broxterman, A. Minnaard, B. Kaptein, S. van der Sluis, L. Hulshof, J. Kooistra, Angew. Chem. 1998, 110, 2491; Angew. Chem. Int. Ed. 1998, 37, 2349.
7. T. Vries, H. Wynberg, E. van Echten, J. I Koek, W. ten Hoeve, R. M. Kellogg, Q. M. Broxterman, A. Minnaard, B. Kaptein, S. van der Sluis, L. Hulshof, J. Kooistra, Angew. Chem. 1998, 110, 2491; Angew. Chem. Int. Ed. 1998, 37, 2349.
8. O. Dapremont, F. Geiser, T. Zhang, S. S. Guhan, R. M. Guinn, G. J. Quallich, US Pat. 6444854, 2002.
9. W. M. Welch, A. R. Kraska, R. Sarges, B. K. Koe, J. Med. Chem. 1984, 27, 1508.
10. In favorable cases, the benefits of continuous chromatography outweigh the capital expense for specialty equipment, which can be operated internally or at a specialist company.
11. Stoichiometric chiral ligands (chiral mediators) do not require attachment and cleavage steps and in an optimized case can be recycled in the same reaction vessel by in situ regeneration of the active species: A. Choudhury, J. R. Moore, M. E. Pierce, J. M. Fortunak, I. Valvis, P. N. Confalone, Org. Process Res. Dev. 2003, 7, 324.
12. A. Piscopio, J. M. Hawkins, S. Caron, S. E. Kelly, J. W. Raggon, M. J. Castaldi, R. W. Dugger, S. G. Ruggeri, US. Pat 6096906, 2000.
13. G. J. Quallich, T. M. Woodall, Tetrahedron 1992, 48, 10239.
14. I. B. Repinskaya, K. Y. Koltunov, Sib. Khim. Zh. 1993, 3, 73.
15. For other multistep routes to sertraline tetralone (S)-1 by using asymmetric catalysis, see: E. J. Corey, T. G. Gant, Tetrahedron Lett. 1994, 35, 5373; M. Lautens, T. Rovis, J. Org. Chem. 1997, 62, 5246; H. M. L. Davies, D. G. Stafford, T. Hansen, Org. Lett. 1999, 1, 233.
16. For other multistep routes to sertraline tetralone (S)-1 by using asymmetric catalysis, see: E. J. Corey, T. G. Gant, Tetrahedron Lett. 1994, 35, 5373; M. Lautens, T. Rovis, J. Org. Chem. 1997, 62, 5246; H. M. L. Davies, D. G. Stafford, T. Hansen, Org. Lett. 1999, 1, 233.
17. For other multistep routes to sertraline tetralone (S)-1 by using asymmetric catalysis, see: E. J. Corey, T. G. Gant, Tetrahedron Lett. 1994, 35, 5373; M. Lautens, T. Rovis, J. Org. Chem. 1997, 62, 5246; H. M. L. Davies, D. G. Stafford, T. Hansen, Org. Lett. 1999, 1, 233.
18. G. J. Quallich, PCT Int. Appl. WO 9502585, 1995.
19. T. D. Machajewski, C.-H. Wong, Angew. Chem. 2000, 112, 1406; Angew. Chem. Int. Ed. 2000, 39, 1352.
20. T. D. Machajewski, C.-H. Wong, Angew. Chem. 2000, 112, 1406; Angew. Chem. Int. Ed. 2000, 39, 1352.
21. 2 2003, April issue, 26.
22. For example, the scarce supply and expense of binap prompted Merck chemists to develop a simple and efficient synthesis of binap: D. Cai, J. E Payack, D. R. Bender, D. L. Hughes, T. R. Verhoeven, P. J. Reider, J. Org. Chem. 1994, 59, 7180.
23. Palladium prices from http://www.kitco.com/charts/historicalpalladium. html. We thank Dr. Don Zeng of Heraeus for pointing out this internet reference.
24. S. Challenger, A. Derrick, C. P. Mason, T. V. Silk, Tetrahedron Lett. 1999, 40, 2187.
25. M. J. Burk, F. Bienewald, S. Challenger, A. Derrick, J. A. Ramsden, J. Org. Chem. 1999, 64, 3290.
26. M. Bulliard, B. Laboue, J. Lastennet, S. Roussiasse, Org. Process Res. Dev. 2001, 5, 438.
27. Crystallization of the product of an asymmetric catalytic reaction, a step often included to enhance the optical purity, can contribute to the robustness of the process (for example, in the case of varying selectivity), provided that the optical purity does not drop below the eutectic composition.